- 专利标题: METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
-
申请号: US17015995申请日: 2020-09-09
-
公开(公告)号: US20210052649A1公开(公告)日: 2021-02-25
- 发明人: Michael C. Jensen , Stanley R. Riddell , Michael Hudecek
- 申请人: Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
- 申请人地址: US WA Seattle; US WA Seattle
- 专利权人: Fred Hutchinson Cancer Research Center,Seattle Children's Hospital, dba Seattle Children's Research Institute
- 当前专利权人: Fred Hutchinson Cancer Research Center,Seattle Children's Hospital, dba Seattle Children's Research Institute
- 当前专利权人地址: US WA Seattle; US WA Seattle
- 主分类号: A61K35/17
- IPC分类号: A61K35/17 ; C07K14/705 ; C07K14/725 ; C07K14/715 ; C07K16/28 ; C07K16/32 ; C07K16/40
摘要:
The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
信息查询
IPC分类: